Medicus Pharma (MDCX) Research & Development (2024 - 2025)
Medicus Pharma (MDCX) posted Research & Development of $3.6 million for Q4 2025, up 112.9% quarter-over-quarter from $1.7 million in Q3 2025, and up 162.76% year-on-year from $1.4 million in Q4 2024.
Medicus Pharma (MDCX) Research & Development (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Research & Development for 2 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- Research & Development for Q4 2025 came in at $3.6 million, up 162.76% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.7 million (up 194.15% YoY), and the FY2025 annual result was $8.7 million, up 147.11% from the prior year.
- Research & Development was $3.6 million for Q4 2025 at Medicus Pharma, up from $1.7 million in the prior quarter.
- Over five years, Research & Development peaked at $3.6 million in Q4 2025 and troughed at $321377.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 3.53 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 2.47 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | 3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 2.01 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 321,377.00 |